Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 267

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Digital Drug Safety Surveillance: Monitoring Pharmaceutical Products in Twitter

Open access
Freifeld, Clark C., Brownstein, John S., Menone, Christopher M., Bao, Wenjie, Filice, Ross, Kass-Hout, Taha, Dasgupta, Nabarun·2014·Drug Safety

Abstract

BACKGROUND: Traditional adverse event (AE) reporting systems have been slow in adapting to online AE reporting from patients, relying instead on gatekeepers, such as clinicians and drug safety groups, to verify each potential event. In the meantime, increasing numbers of patients have turned to social media to share their experiences with drugs, medical devices, and vaccines. OBJECTIVE: The aim of the study was to evaluate the level of concordance between Twitter posts mentioning AE-like reactions and spontaneous reports received by a regulatory agency. METHODS: We collected public English-language Twitter posts mentioning 23 medical products from 1 November 2012 through 31 May 2013. Data were filtered using a semi-automated process to identify posts with resemblance to AEs (Proto-AEs). A dictionary was developed to translate Internet vernacular to a standardized regulatory ontology for analysis (MedDRA(®)). Aggregated frequency of identified product-event pairs was then compared with data from the public FDA Adverse Event Reporting System (FAERS) by System Organ Class (SOC). RESULTS: Of the 6.9 million Twitter posts collected, 4,401 Proto-AEs were identified out of 60,000 examined. Automated, dictionary-based symptom classification had 86 % recall and 72 % precision [corrected]. Similar overall distribution profiles were observed, with Spearman rank correlation rho of 0.75 (p < 0.0001) between Proto-AEs reported in Twitter and FAERS by SOC. CONCLUSION: Patients reporting AEs on Twitter showed a range of sophistication when describing their experience. Despite the public availability of these data, their appropriate role in pharmacovigilance has not been established. Additional work is needed to improve data acquisition and automation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40264-014-0155-x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 6

  1. Center for Drug Evaluation, Research. FDA adverse events reporting system (FAERS)—FDA adverse event reporting system (FAERS): latest quarterly data files. fda.gov. Center for drug evaluation and research.
  2. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). EMA; London; 2012:1–84.
  3. US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. US FDA; Silver Spring (MD); 2009:1–43.
  4. Association of the British Pharmaceutical Industry. Pharmacovigilance Expert Network. Guidance notes on the management of adverse events and product complaints from digital media. 2nd ed. London; ABPI; 2013:1–14.
  5. 52 Cool Facts About Social Media—2012 Edition #socialmedia—Danny Brown [Internet]. dannybrown.me. Cited 25 Nov 2013. http://dannybrown.me/2012/06/06/52-cool-facts-social-media-2012/ .
  6. Edwards IR, Lindquist M. Social media and networks in pharmacovigilance: boon or bane? Drug Saf. 2011;34:267–71. · doi:10.2165/11590720-000000000-00000

Cited by

See all 267

Metadata

Authors
Freifeld, C. C., Brownstein, J. S., Menone, C. M., Bao, W., Filice, R., Kass-Hout, T., & Dasgupta, N.
Venue
Drug Safety
Published
2014-04-29
Volume
37
Issue
5
Pages
343-350
ISSN
  • 0114-5916 (ISSN-L)
  • 1179-1942
OpenAlex
W2165530491
Cited by
267
References
9
FWCI
55.65
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Digital Drug Safety Surveillance: Monitoring Pharmaceutical Products in Twitter. https://app.cochat.ai/papers/10.1007/s40264-014-0155-x
The paper
Freifeld, C. C., Brownstein, J. S., Menone, C. M., Bao, W., Filice, R., Kass-Hout, T., & Dasgupta, N. (2014). Digital Drug Safety Surveillance: Monitoring Pharmaceutical Products in Twitter. Drug Safety. https://doi.org/10.1007/s40264-014-0155-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.